Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TELA | Common Stock | Sale | -$1.79M | -378K | -13.33% | $4.74 | 2.46M | Jun 28, 2024 | See footnotes | F1, F2 |
transaction | TELA | Common Stock | Sale | -$64.1K | -13.7K | -0.56% | $4.68 | 2.44M | Jul 1, 2024 | See footnotes | F1, F2 |
transaction | TELA | Common Stock | Sale | -$166K | -36.6K | -1.5% | $4.54 | 2.41M | Jul 2, 2024 | See footnotes | F1, F2 |
Orbimed Advisors Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP IV. By virtue of such relationships, OrbiMed Advisors and GP IV may be deemed to have voting power and investment power over the securities held by OPI IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI IV. |
F2 | Each of OrbiMed Advisors and GP IV disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |